Search Results

You are looking at 101 - 110 of 744 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, and Jeffrey D. Wayne

stromal tumors. 15 Recurrence after resection is predominantly intra-abdominal, and the liver is the most common site of recurrence in patients with primary presentation and those with metastatic disease at presentation. 16 Lymph node metastases are

Full access

Ami M. Vyas, Hilary Aroke, and Stephen J. Kogut

metastases) at 3.2%. Conclusion: Almost one quarter of the study cohort did not receive guideline-concordant care. There are opportunities to improve cancer care for women with negative HR status who have lower socioeconomic status. The high unexplained

Full access

Maral DerSarkissian, Shuanglian Li, Aaron Galaznik, Rachel Bhak, Iryna Bocharova, Thomas Kulalert, Huamao M. Lin, Hui Huang, and Mei Sheng Duh

.5%). Among 83 TN and 47 RR patients with known ECOG score at advanced diagnosis, most had score 0–1 (TN: 56.3%; RR: 62.0%). Central nervous system metastases were observed in 35.2% of TN and 33.8% of RR patients. While 45.3% of TN patients received any

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

. This training set outperformed all clinical variables in predicting the likelihood of distant metastases within 5 years in this group of women younger than 55 years of age and with lymph node–negative breast cancer. A subsequent validation study was

Full access

Giuseppe Curigliano

Boston, MA, U.S.A.; Tuesday, 9.40 a.m. Patient: “Doctor, I am very worried about the CT scan report. It says ‘disease progression.’ ‘Progression’ means I have metastases, doesn’t it? How long will I live?” Milan, Italy; Tuesday, 11.00 a

Full access

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber

2 ). Based on the morphology and immunohistochemical profile, a lung primary was favored. A staging PET/CT confirmed the CT findings of at least stage IIIb disease. A brain MRI unfortunately showed 2 small cerebral metastases in the right and left

Full access

Owen Tan, Deborah J. Schofield, and Rupendra Shrestha

from a combination of pathology reports, inpatient notifications, and other treatment facilities. The variable was categorized as localized to tissue of origin, regional spread, adjacent organs and/or regional lymph nodes, distant metastases, and

Full access

Fei Gao, Nan Li, YongMei Xu, and GuoWang Yang

-related mortality and can have a harmful effect on these patients, and was associated with a significant decrease in survival. For patients with <6 positive lymph node metastases who did not receive POCT, however, RT can improve survival time, and for patients with

Full access

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

), and presence of distant metastases (M0 vs M1). Presence of nodal or distant metastases is recorded in the NCDB before treatment based on coding from patient medical records. The PSA cutoff of ≥98.0 ng/mL was chosen due to limitations in the NCDB: all

Full access

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

Despite surgery with curative intent, approximately 50% of patients with muscle-invasive transitional cell carcinoma of the bladder will develop distant metastases and succumb to their disease. Attempts to improve outcomes have focused on refining surgical techniques and integrating perioperative chemotherapy. This review summarizes the available literature addressing the role of pelvic lymphadenectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy in the management of patients with muscle-invasive transitional cell carcinoma of bladder.